nach oben

Current Diabetes Reports

Erschienen in:

01.12.2012 | Psychosocial Aspects (K Hood, Section Editor)

Quality of Life and Technology: Impact on Children and Families With Diabetes

verfasst von: Masakazu Hirose, Elizabeth A. Beverly, Katie Weinger

Erschienen in: Current Diabetes Reports | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Ensuring quality of life (QOL) while maintaining glycemic control within targets is an important challenge in type 1 and type 2 diabetes treatment. For children with diabetes, QOL includes enjoying meals, feeling safe in school, and perceiving positive, supportive relationships with parents, siblings, and friends. Yet many treatment-related and psychosocial barriers can interfere with a child’s QOL and their ability to manage diabetes effectively. Diabetes management also imposes considerable lifestyle demands that are difficult and often frustrating for children to negotiate at a young age. Recent advances in diabetes medications and technologies have improved glycemic control in children with diabetes. Two widely used technologies are the insulin pump and continuous glucose monitoring (CGM) system. These technologies provide patients with more flexibility in their daily life and information about glucose fluctuations. Several studies report improvements in glycemic control in children with type 1 diabetes using the insulin pump or sensor-augmented pump therapy. Importantly, these technologies may impact QOL for children and families with diabetes, although they are rarely used or studied in the treatment of children with type 2 diabetes. Further, emerging closed loop and web- and phone-based technologies have great potential for supporting diabetes self-management and perhaps QOL. A deeper understanding and appreciation of the impact of diabetes technology on children’s and parents’ QOL is critical for both the medical and psychological care of diabetes. Thus, the purpose of this review is to discuss the impact of new diabetes technologies on QOL in children, adolescents and families with type 1 diabetes.

Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient’s perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003;6:522–31.PubMedCrossRef

McLeod LD, Coon CD, Martin SA, et al. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:163–9.PubMedCrossRef

Faulkner MS, Clark FS. Quality of life for parents of children and adolescents with type 1 diabetes. Diabetes Educ. 1998;24:721–7.PubMedCrossRef

Barnard KD, Lloyd CE, Skinner TC. Systematic literature review: quality of life associated with insulin pump use in type 1 diabetes. Diabet Med. 2007;24:607–17.PubMedCrossRef

Wallander JL, Schmitt M, Koot HM. Quality of life measurement in children and adolescents: issues, instruments, and applications. J Clin Psychol. 2001;57:571–85.PubMedCrossRef

Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion vs multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol. 2010;47:77–81.PubMedCrossRef

Pankowska E, Blazik M, Dziechciarz P, et al. Continuous subcutaneous insulin infusion vs multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes. 2009;10:52–8.PubMedCrossRef

Golicki DT, Golicka D, Groele L, Pankowska E. Continuous Glucose Monitoring System in children with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetologia. 2008;51:233–40.PubMedCrossRef

Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011;343:d3805.PubMedCrossRef

10.

Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care. 2003;26:1079–87.PubMedCrossRef

11.

Mulvaney SA, Schlundt DG, Mudasiru E, et al. Parent perceptions of caring for adolescents with type 2 diabetes. Diabetes Care. 2006;29:993–7.PubMedCrossRef

12.

Peyrot M. The DAWN Youth WebTalk Study: methods, findings, and implications. Pediatr Diabetes. 2009;10 Suppl 13:37–45.PubMedCrossRef

13.

Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26:2598–603.PubMedCrossRef

14.

Bode BW. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy vs multiple daily injections. Clin Ther. 2007;29(Suppl D):S135–44.PubMedCrossRef

15.

Polisena J, Tran K, Cimon K, et al. Home telehealth for diabetes management: a systematic review and meta-analysis. Diabetes Obes Metab. 2009;11:913–30.PubMedCrossRef

16.

Anderson RM, Donnelly MB, Gorenflo DW, et al. Influencing the attitudes of medical students toward diabetes. Results of a controlled study. Diabetes Care. 1993;16:503–5.PubMedCrossRef

17.

The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial. Diabetes Care. 1996;19:195–203.

18.

Hoey H, Aanstoot HJ, Chiarelli F, et al. Good metabolic control is associated with better quality of life in 2101 adolescents with type 1 diabetes. Diabetes Care. 2001;24:1923–8.PubMedCrossRef

19.

Guttmann-Bauman I, Flaherty BP, Strugger M, McEvoy RC. Metabolic control and quality-of-life self-assessment in adolescents with IDDM. Diabetes Care. 1998;21:915–8.PubMedCrossRef

20.

Jacobson AM, Hauser ST, Lavori P, et al. Family environment and glycemic control: a 4 year prospective study of children and adolescents with insulin-dependent diabetes mellitus. Psychosom Med. 1994;56:401–9.PubMed

21.

Wysocki T. Associations among teen-parent relationships, metabolic control, and adjustment to diabetes in adolescents. J Pediatr Psychol. 1993;18:441–52.PubMedCrossRef

22.

Nardi L, Zucchini S, D’Alberton F, et al. Quality of life, psychological adjustment, and metabolic control in youths with type 1 diabetes: a study with self- and parent-report questionnaires. Pediatr Diabetes. 2008;9:496–503.PubMedCrossRef

23.

Wake M, Hesketh K, Cameron F. The Child Health Questionnaire in children with diabetes: cross-sectional survey of parent and adolescent-reported functional health status. Diabet Med. 2000;17:700–7.PubMedCrossRef

24.

Anderson BJ, Vangsness L, Connell A, et al. Family conflict, adherence, and glycaemic control in youth with short duration type 1 diabetes. Diabet Med. 2002;19:635–42.PubMedCrossRef

25.

Schafer LC, McCaul KD, Glasgow RE. Supportive and nonsupportive family behaviors: relationships to adherence and metabolic control in persons with type I diabetes. Diabetes Care. 1986;9:179–85.PubMedCrossRef

26.

Weinger K, O’Donnell KA, Ritholz MD. Adolescent views of diabetes-related parent conflict and support: a focus group analysis. J Adolesc Health. 2001;29:330–6.PubMedCrossRef

27.

Anderson B, Coyne JC. Miscarried helping in the families of children and adolescents with chronic disease. In: Jhonson JH, Jhonson SB, editors. Advances in child health psychology. Gainesville: University of Florida Press; 1991. p. 167–77.

28.

Miller-Johnson S, Emery RE, Marvin RS, et al. Parent-child relationships and the management of insulin-dependent diabetes mellitus. J Consult Clin Psychol. 1994;62:603–10.PubMedCrossRef

29.

Hauser ST, Jacobson AM, Lavori P, et al. Adherence among children and adolescents with insulin-dependent diabetes mellitus over a four-year longitudinal follow-up: II. Immediate and long-term linkages with the family milieu. J Pediatr Psychol. 1990;15:527–42.PubMedCrossRef

30.

Laffel LM, Connell A, Vangsness L, et al. General quality of life in youth with type 1 diabetes: relationship to patient management and diabetes-specific family conflict. Diabetes Care. 2003;26:3067–73.PubMedCrossRef

31.

Faulkner MS, Chang LI. Family influence on self-care, quality of life, and metabolic control in school-age children and adolescents with type 1 diabetes. J Pediatr Nurs. 2007;22:59–68.PubMedCrossRef

32.

• Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med. 2012;366:1616–24. This feature reviews the major clinical trials using insulin pump therapy and discusses the clinical benefits of this technology and potential adverse effects..PubMedCrossRef

33.

Mednick L, Cogen FR, Streisand R. Satisfaction and quality of life in children with type 1 diabetes and their parents following transition to insulin pump therapy. Children’s Health Care. 2004;33:169–83.CrossRef

34.

Nuboer R, Borsboom GJ, Zoethout JA, et al. Effects of insulin pump vs injection treatment on quality of life and impact of disease in children with type 1 diabetes mellitus in a randomized, prospective comparison. Pediatr Diabetes. 2008;9:291–6.PubMedCrossRef

35.

Weintrob N, Benzaquen H, Galatzer A, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics. 2003;112:559–64.PubMedCrossRef

36.

Doyle EA, Weinzimer SA, Steffen AT, et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004;27:1554–8.PubMedCrossRef

37.

Varni JW, Burwinkle TM, Jacobs JR, et al. The PedsQL in type 1 and type 2 diabetes: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales and type 1 Diabetes Module. Diabetes Care. 2003;26:631–7.PubMedCrossRef

38.

Muller-Godeffroy E, Treichel S, Wagner VM. Investigation of quality of life and family burden issues during insulin pump therapy in children with Type 1 diabetes mellitus–a large-scale multicentre pilot study. Diabet Med. 2009;26:493–501.PubMedCrossRef

39.

Low KG, Massa L, Lehman D, Olshan JS. Insulin pump use in young adolescents with type 1 diabetes: a descriptive study. Pediatr Diabetes. 2005;6:22–31.PubMedCrossRef

40.

Patton SR, Williams LB, Dolan LM, et al. Feeding problems reported by parents of young children with type 1 diabetes on insulin pump therapy and their associations with children’s glycemic control. Pediatr Diabetes. 2009;10:455–60.PubMedCrossRef

41.

Grossman HY, Brink S, Hauser ST. Self-efficacy in adolescent girls and boys with insulin-dependent diabetes mellitus. Diabetes Care. 1987;10:324–9.PubMedCrossRef

42.

Littlefield CH, Craven JL, Rodin GM, et al. Relationship of self-efficacy and binging to adherence to diabetes regimen among adolescents. Diabetes Care. 1992;15:90–4.PubMedCrossRef

43.

McMahon SK, Airey FL, Marangou DA, et al. Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life. Diabet Med. 2005;22:92–6.PubMedCrossRef

44.

Battaglia MR, Alemzadeh R, Katte H, et al. Brief report: disordered eating and psychosocial factors in adolescent females with type 1 diabetes mellitus. J Pediatr Psychol. 2006;31:552–6.PubMedCrossRef

45.

Sullivan-Bolyai S, Knafl K, Tamborlane W, Grey M. Parents’ reflections on managing their children’s diabetes with insulin pumps. J Nurs Scholarsh. 2004;36:316–23.PubMedCrossRef

46.

Fox LA, Buckloh LM, Smith SD, et al. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care. 2005;28:1277–81.PubMedCrossRef

47.

Wilson DM, Buckingham BA, Kunselman EL, et al. A 2-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care. 2005;28:15–9.PubMedCrossRef

48.

Opipari-Arrigan L, Fredericks EM, Burkhart N, et al. Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus. Pediatr Diabetes. 2007;8:377–83.PubMedCrossRef

49.

Nabhan ZM, Kreher NC, Greene DM, et al. A randomized prospective study of insulin pump vs insulin injection therapy in very young children with type 1 diabetes: 12-month glycemic, BMI, and neurocognitive outcomes. Pediatr Diabetes. 2009;10:202–8.PubMedCrossRef

50.

Skogsberg L, Fors H, Hanas R, et al. Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs multiple daily injections in children at onset of type 1 diabetes mellitus. Pediatr Diabetes. 2008;9:472–9.PubMedCrossRef

51.

Ritholz MD, Smaldone A, Lee J, et al. Perceptions of psychosocial factors and the insulin pump. Diabetes Care. 2007;30:549–54.PubMedCrossRef

52.

Phillip M, Battelino T, Rodriguez H, et al. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2007;30:1653–62.PubMedCrossRef

53.

DiMeglio LA, Pottorff TM, Boyd SR, et al. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr. 2004;145:380–4.PubMedCrossRef

54.

Jakisch BI, Wagner VM, Heidtmann B, et al. Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years. Diabet Med. 2008;25:80–5.PubMedCrossRef

55.

Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care. 2002;25:593–8.PubMedCrossRef

56.

Bending JJ, Pickup JC, Keen H. Frequency of diabetic ketoacidosis and hypoglycemic coma during treatment with continuous subcutaneous insulin infusion. Audit of medical care. Am J Med. 1985;79:685–91.PubMedCrossRef

57.

Berlin KS, Davies WH, Jastrowski KE, et al. Contextual assessment of problematic situations identified by insulin pump using adolescents and their parents. Families Syst Health. 2006;24:33–44.CrossRef

58.

Katz ML, Volkening LK, Anderson BJ, Laffel LM. Contemporary rates of severe hypoglycaemia in youth with type 1 diabetes: variability by insulin regimen. Diabet Med. 2012;29(7):926–32.

59.

Shalitin S, Gil M, Nimri R, et al. Predictors of glycaemic control in patients with type 1 diabetes commencing continuous subcutaneous insulin infusion therapy. Diabet Med. 2010;27:339–47.PubMedCrossRef

60.

Haugstvedt A, Wentzel-Larsen T, Graue M, et al. Fear of hypoglycaemia in mothers and fathers of children with type 1 diabetes is associated with poor glycaemic control and parental emotional distress: a population-based study. Diabet Med. 2010;27:72–8.PubMedCrossRef

61.

Bierschbach JL, Cooper L, Liedl JA. Insulin pumps: what every school nurse needs to know. J Sch Nurs. 2004;20:117–23.PubMedCrossRef

62.

Weissberg-Benchell J, Goodman SS, Antisdel Lomaglio J, Zebracki K. The use of Continuous Subcutaneous Insulin Infusion (CSII): parental and professional perceptions of self-care mastery and autonomy in children and adolescents. J Pediatr Psychol. 2007;32:1196–202.PubMedCrossRef

63.

Alsaleh FM, Smith FJ, Taylor KM. Experiences of children/young people and their parents, using insulin pump therapy for the management of type 1 diabetes: qualitative review. J Clin Pharm Ther. 2012;37:140–7.PubMedCrossRef

64.

Paris CA, Imperatore G, Klingensmith G, et al. Predictors of insulin regimens and impact on outcomes in youth with type 1 diabetes: the SEARCH for Diabetes in Youth study. J Pediatr. 2009;155:183e1–9e1.

65.

Johns C, Faulkner MS, Quinn L. Characteristics of adolescents with type 1 diabetes who exhibit adverse outcomes. Diabetes Educ. 2008;34:874–85.PubMedCrossRef

66.

Delamater AM, Albrecht DR, Postellon DC, Gutai JP. Racial differences in metabolic control of children and adolescents with type I diabetes mellitus. Diabetes Care. 1991;14:20–5.PubMedCrossRef

67.

Gallegos-Macias AR, Macias SR, Kaufman E, et al. Relationship between glycemic control, ethnicity and socioeconomic status in Hispanic and white non-Hispanic youths with type 1 diabetes mellitus. Pediatr Diabetes. 2003;4:19–23.PubMedCrossRef

68.

Chalew SA, Gomez R, Butler A, et al. Predictors of glycemic control in children with type 1 diabetes: the importance of race. J Diabetes Complications. 2000;14:71–7.PubMedCrossRef

69.

Klingensmith G, Kaufman F, Schatz D, Clarke W. Care of children with diabetes in the school and day care setting. Diabetes Care. 2003;26 Suppl 1:S131–5.PubMed

70.

Wagner VM, Muller-Godeffroy E, von Sengbusch S, et al. Age, metabolic control and type of insulin regime influences health-related quality of life in children and adolescents with type 1 diabetes mellitus. Eur J Pediatr. 2005;164:491–6.PubMedCrossRef

71.

Spencer J, Cooper H, Milton B. Qualitative studies of type 1 diabetes in adolescence: a systematic literature review. Pediatr Diabetes. 2010;11:364–75.PubMedCrossRef

72.

Darby W. The experiences of school nurses caring for students receiving continuous subcutaneous insulin infusion therapy. J Sch Nurs. 2006;22:336–44.PubMedCrossRef

73.

Weinzimer SA, Ahern JH, Doyle EA, et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics. 2004;114:1601–5.PubMedCrossRef

74.

Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA. 2006;295:1707–8.PubMedCrossRef

75.

Ceriello A, Ihnat MA. ‘Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting. Diabet Med. 2010;27:862–7.PubMedCrossRef

76.

Kilpatrick ES, Rigby AS, Atkin SL. For debate. Glucose variability and diabetes complication risk: we need to know the answer. Diabet Med. 2010;27:868–71.PubMedCrossRef

77.

Kashmer L, Clarke W, Gurka M, et al. Predictors of parental interest in continuous glucose monitoring for children with type 1 diabetes. Diabetes Technol Ther. 2009;11:373–8.PubMedCrossRef

78.

Cemeroglu AP, Stone R, Kleis L, et al. Use of a real-time continuous glucose monitoring system in children and young adults on insulin pump therapy: patients’ and caregivers’ perception of benefit. Pediatr Diabetes. 2010;11:182–7.PubMedCrossRef

79.

Chase HP, Kim LM, Owen SL, et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics. 2001;107:222–6.PubMedCrossRef

80.

• Mauras N, Beck R, Xing D, et al. A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to <10 years. Diabetes Care. 2012;35:204–10. This is the most recently published randomized controlled trial evaluating QOL with real-time CGM in children with type 1 diabetes. This study found a high degree of parental satisfaction with CGM..PubMedCrossRef

81.

•• Beck RW, Lawrence JM, Laffel L, et al. Quality-of-life measures in children and adults with type 1 diabetes: Juvenile Diabetes Research Foundation Continuous Glucose Monitoring randomized trial. Diabetes Care. 2010;33:2175–7. This study found high levels of satisfacion with CGM, but reported no differrences in QOL between a CGM group and control grous in patients <18 years of age and their parents..PubMedCrossRef

82.

• Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–20. This one-year randomized controlled trial showed that both adult and children using CGM and the insulin pump improved HbA1c. It also showed that an increased frequency of sensor use was associated with a greater reduction in HbA1c level..PubMedCrossRef

83.

•• Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464–76. This large randomized controlled study showed improvement inHbA1c in the adult group, but no differences in the 8–14 year old and 15–24 year old groups..PubMedCrossRef

84.

Markowitz JT, Pratt K, Aggarwal J, et al. Psychosocial correlates of continuous glucose monitoring use in youth and adults with type 1 diabetes and parents of youth. Diabetes Technol Ther. 2012.

85.

Ramchandani N, Arya S, Ten S, Bhandari S. Real-life utilization of real-time continuous glucose monitoring: the complete picture. J Diabetes Sci Technol. 2011;5:860–70.PubMed

86.

•• Harris MA, Wysocki T, Sadler M, et al. Validation of a structured interview for the assessment of diabetes self-management. Diabetes Care. 2000;23:1301–4. This review discusses the use of technology to improve diabetes management and glycemic control in this teens with diabetes..PubMedCrossRef

87.

Psychological aspects of continuous glucose monitoring in pediatric type 1 diabetes. Pediatr Diabetes. 2006;7:32–8.

88.

Tansey M, Laffel L, Cheng J, et al. Satisfaction with continuous glucose monitoring in adults and youths with type 1 diabetes. Diabet Med. 2011;28:1118–22.PubMedCrossRef

89.

Youth and parent satisfaction with clinical use of the GlucoWatch G2 Biographer in the management of pediatric type 1 diabetes. Diabetes Care. 2005;28:1929–35.

90.

Tsalikian E, Fox L, Weinzimer S, et al. Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. Pediatr Diabetes. 2011;13(4):301–7.

91.

McQueen RB, Ellis SL, Campbell JD, et al. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc. 2011;9:13.PubMedCrossRef

92.

Whittemore R, Grey M, Lindemann E, et al. Development of an Internet coping skills training program for teenagers with type 1 diabetes. Comput Inform Nurs. 2010;28:103–11.PubMedCrossRef

93.

Mulvaney SA, Rothman RL, Osborn CY, et al. Self-management problem solving for adolescents with type 1 diabetes: intervention processes associated with an Internet program. Patient Educ Couns. 2011;85:140–2.PubMedCrossRef

94.

Mulvaney SA, Rothman RL, Wallston KA, et al. An internet-based program to improve self-management in adolescents with type 1 diabetes. Diabetes Care. 2010;33:602–4.PubMedCrossRef

95.

Harris MA, Hood KK, Mulvaney SA. Pumpers, skypers, surfers, and texters: technology to improve the management of diabetes in teenagers. Diabetes Obes Metab. 2012. doi:10.1111/j.1463-1326.2012.01599.x.

96.

Hanauer DA, Wentzell K, Laffel N, Laffel LM. Computerized Automated Reminder Diabetes System (CARDS): e-mail and SMS cell phone text messaging reminders to support diabetes management. Diabetes Technol Ther. 2009;11:99–106.PubMedCrossRef

97.

Mulvaney SA, Anders S, Smith AK, et al. A pilot test of a tailored mobile and web-based diabetes messaging system for adolescents. J Telemed Telecare. 2012;18:115–8.PubMedCrossRef

98.

Mulvaney SA, Ritterband LM, Bosslet L. Mobile intervention design in diabetes: review and recommendations. Curr Diab Rep. 2011;11:486–93.PubMedCrossRef

99.

Mulvaney SA, Rothman RL, Dietrich MS, et al. Using mobile phones to measure adolescent diabetes adherence. Health Psychol. 2012;31:43–50.PubMedCrossRef

100.

Liang X, Wang Q, Yang X, et al. Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis. Diabet Med. 2011;28:455–63.PubMedCrossRef

101.

Farrell K, Holmes-Walker DJ. Mobile phone support is associated with reduced ketoacidosis in young adults. Diabet Med. 2011;28:1001–4.PubMedCrossRef

102.

Benhamou PY, Melki V, Boizel R, et al. One-year efficacy and safety of Web-based follow-up using cellular phone in type 1 diabetic patients under insulin pump therapy: the PumpNet study. Diabetes Metab. 2007;33:220–6.PubMedCrossRef

103.

Franklin VL, Waller A, Pagliari C, Greene SA. A randomized controlled trial of Sweet Talk, a text-messaging system to support young people with diabetes. Diabet Med. 2006;23:1332–8.PubMedCrossRef

104.

Carroll AE, DiMeglio LA, Stein S, Marrero DG. Using a cell phone-based glucose monitoring system for adolescent diabetes management. Diabetes Educ. 2011;37:59–66.PubMedCrossRef

105.

Logtenberg SJ, Kleefstra N, Houweling ST, et al. Health-related quality of life, treatment satisfaction, and costs associated with intraperitoneal vs subcutaneous insulin administration in type 1 diabetes: a randomized controlled trial. Diabetes Care. 2010;33:1169–72.PubMedCrossRef

106.

Dunn FL, Nathan DM, Scavini M, et al. Long-term therapy of IDDM with an implantable insulin pump. The implantable insulin pump trial study group. Diabetes Care. 1997;20:59–63.PubMedCrossRef

107.

Logtenberg SJ, Kleefstra N, Houweling ST, et al. Improved glycemic control with intraperitoneal vs subcutaneous insulin in type 1 diabetes: a randomized controlled trial. Diabetes Care. 2009;32:1372–7.PubMedCrossRef

108.

Skyler JS, Jovanovic L, Klioze S, et al. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care. 2007;30:579–85.PubMedCrossRef

109.

Testa MA, Simonson DC. Satisfaction and quality of life with premeal inhaled vs injected insulin in adolescents and adults with type 1 diabetes. Diabetes Care. 2007;30:1399–405.PubMedCrossRef

110.

Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomized controlled studies. BMJ. 2011;342:d1855.PubMedCrossRef

111.

Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomized crossover trial. Lancet. 2010;375:743–51.PubMedCrossRef

112.

El-Khatib FH, Russell SJ, Nathan DM, et al. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2:27ra27.PubMedCrossRef

113.

Wiklund I. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life. Fundam Clin Pharmacol. 2004;18:351–63.PubMedCrossRef

Titel: Quality of Life and Technology: Impact on Children and Families With Diabetes
verfasst von: Masakazu Hirose
Elizabeth A. Beverly
Katie Weinger
Publikationsdatum: 01.12.2012
Verlag: Current Science Inc.
Erschienen in: Current Diabetes Reports / Ausgabe 6/2012
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-012-0313-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2012

Complementary and Alternative Medicine in Diabetes Care

Vitamin D, Immune Tolerance, and Prevention of Type 1 Diabetes

Monogenic Models: What Have the Single Gene Disorders Taught Us?

Health and Psychosocial Outcomes in U.S. Adult Patients with Diabetes from Diverse Ethnicities

The Epigenome and Its Role in Diabetes